The invention relates to a system for treating a biological fluid such as blood or a blood component by selective removal of a target substance, comprising a treatment bag (2) provided with at least one inlet orifice (3) and at least one outlet orifice (4), said treatment bag containing a set of particles (5) having an affinity for the target substance, said set comprising small particles having a size of less than 15 μm, said system further comprising a barrier means (6) composed of at least one porous membrane made of a hydrophilic material, the pores of said membrane being calibrated to a size suitable for preventing the passage of said small particles, namely less than 3 μm.

A dialysis device (100) comprises: a dialyzer for exchange of substances between a blood flow and a dialysate flow in a dialysis area (106) of the dialyzer, wherein the dialyzer comprises a dialyzer membrane (110) for passing toxins in the blood flow to the dialysate flow through pores (112) of the dialyzer membrane (110); and a capacitively coupled generator (120) for generating electromagnetic fields in the dialysis area (106) for loosening electrostatic bonds between toxins and proteins in the blood flow, wherein the generator (120) is capacitively coupled to the blood flow and to the dialysate flow on opposite sides of the dialyzer membrane, and wherein the dialysate membrane (110) is formed of a material having lower conductance than blood and dialysate such that a large electromagnetic field strength is provided across the pores (112) of the dialyzer membrane (110).

An object of the present invention is to provide a ligand-immobilized sea-island composite fiber in which generation of fine particles due to peeling of a sea component from an island component and generation of fine particles due to destruction of a fragile sea component are both suppressed. The present invention provides a sea-island composite fiber comprising a sea component and island components, in which a value (L/S) obtained by dividing the average total length (L) of the perimeter of all island components in a cross section perpendicular to the fiber axis by the average cross-sectional area (S) of the cross section is from 1.0 to 50.0 μm.sup.−1, a distance from the surface to the outermost island component is 1.9 μm or less, and an amino group-containing compound is covalently bonded to a polymer constituting the sea component at a charge density of 0.1 μmol or more and less than 500 μmol per 1 gram dry weight.

The invention relates generally to methods of treating or reducing the risk of Cytokine Release Syndrome (CRS), treating or reducing the risk of Tumor Lysis Syndrome (TLS), or increasing drug exposure in a subject undergoing CAR T-cell therapy or chemotherapy. The methods comprise contacting blood from the subject with an extracorporeal membrane having a plurality of pores having an average pore size of at least 60 kDa to permit inflammatory cytokines, other inflammatory molecules, or metabolites to pass through the pores and out of the blood that is returned back to the subject.

A column for removal of a component from a fluid is disclosed. The column has a compartment with a cross sectional area. The compartment contains beads having a diameter. A ligand selected to bind to the component is coupled to the beads. The cross-sectional area and bead diameter are selected to maintain a flow velocity of the fluid within the compartment below a first threshold, thereby reducing leaching of the ligand into the fluid. Also described herein is an adsorbent comprising a ligand that is attached to a substrate by an amine bond, wherein the ligand is resistant to dissociation from the substrate.

A method for detoxifying a patient's blood by removing bilirubin from the patient's blood includes obtaining a batch of blood from the patient; controlling a pH of the blood so as to maintain the pH at approximately pH 7.4; controlling a temperature of the blood so as to maintain the temperature at approximately 37° C.; providing date pit-derived activated carbon; soaking the date pit-derived activated carbon within the blood for approximately 10-16 hours; and returning the detoxified blood to the patient.

The present disclosure concerns a method for preparing an extracorporeal blood circuit for its use in a blood treatment of a patient, which treatment is carried out using a blood treatment apparatus and using a blood treatment device, which comprises a blood chamber and a dialysate chamber partitioned off therefrom by a membrane, The method comprising: filling the extracorporeal blood circuit using a priming solution, wherein the priming solution comprises citrate, or filling of the extracorporeal blood circuit using a priming solution and using a citrate solution. The invention further comprises devices suitable for carrying out the method.

A blood treatment system comprising at least one first device and at least one second device, wherein the first device is a membrane filter for the removal of toxic mediators from blood and the second device is suitable for the removal of granulocytes and monocytes from blood. The first device has a first blood flow path a first blood flow path for conducting blood through and the second device has a second blood flow path. The first and second devices are serially connected in succession in such a way that the first blood flow path is in fluid communication with the second blood flow path.

The membrane has an interior filter space in its housing and a semipermeable membrane arranged in the interior filter space, which membrane divides the interior filter space into a retentate chamber and permeate chamber. The housing has a blood inlet device and a blood outlet device that are in fluid communication with the retentate chamber, as well as a permeate outlet for diverting permeate from the permeate chamber. The blood inlet device, the retentate chamber and the blood outlet device form the first blood flow path. The membrane filter has a separation characteristic such that the sieve coefficient for albumin, SK.sub.Alb, is within the range from 0.015 to 0.35.

Embodiments provide methods and apparatus for fabricating blood products, such as platelet-rich plasma, containing elevated concentrations of growth factors such as platelet derived growth factor. The platelet-rich plasma can be autologous, and the concentration of growth factors (e.g., platelet derived growth factor) is elevated relative to other samples isolated from the same subject. The platelet-rich plasma can be used to promote tissue regeneration, including wound healing, joint repair, hair growth, and the like. The compositions can be combined with stem cells and used to treat disorders otherwise treated with stem cells. The growth factors present in the samples can direct the differentiation of the stem cells.

A microneedle patch is described that can be used for the sustained delivery of therapeutic agents into living tissue (e.g., skin). The polymer (gelatin methacryloyl (GelMA)) patch can adjust delivery rates based on the degree of crosslinking. The anticancer drug Doxorubicin (DOX) was loaded into GelMA microneedles using a molding fabrication technique. The GelMA microneedles efficiently penetrated the stratum corneum layer of a mouse cadaver skin. Mechanical properties and therapeutic agent release behavior of the GelMA microneedles can be adjusted by tuning the degree of crosslinking. The efficacy of the DOX released from the GelMA microneedles was tested and demonstrated the anticancer efficacy of the released drugs against melanoma cell line A375. Because GelMA is versatile material in engineering tissue scaffolds, GelMA microneedles can be used as a platform for the delivery of various types of therapeutic agents to tissue.